AI assistant
SynAct Pharma Board/Management Information 2023
3114_rns_2023-05-15_97eb342f-6ac6-4305-b2cf-f8fafd3136e8.pdf
Board/Management Information
Open in viewerOpens in your device viewer
SynAct Pharma appoints Björn Westberg as CFO
SynAct Pharma AB (publ) ("SynAct") today announced that Björn Westberg has been appointed Chief Financial Officer and member of the management team at SynAct. Björn has extensive experience from the life science sector, from smaller pharmaceutical companies to contract manufacturing and "Big Pharma". He served as a CFO of several listed companies and most recently comes from his role as CFO at Attgeno.
Björn has more than 25 years of experience in the life science sector and has served as a chief financial officer since 2001. Prior to his role at privately held Attgeno, he was CFO at global cloud software company Enea, Swedish medtech Bonesupport, both of which are listed on Nasdaq Stockholm, and pharmaceutical developer and manufacturer Recipharm. He started his career at AstraZeneca where he worked in various capacities from 1989-2001.
"SynAct Pharma is at a critical point in its path to become a global leader in inflammatory diseases such as rheumatoid arthritis," said Chairman Torbjørn Bjerke, who is set to become CEO on May 25. "The company is ready to take the next step forward, and we have a lot of work to do preparing our potential partners and shareholders for the next clinical results. We are pleased to have Björn join us as CFO and are confident his wealth of experience will be a welcome addition to the team as we work to execute on our growth plans."
"I'm excited at the opportunity to join SynAct at such an important time in its development," said Björn Westberg. "The SynAct team has accomplished a lot over the past several years from joining the main list in Stockholm, gaining new investors and driving its development platform. I look forward to joining the team."
Björn Westberg will take up the position full-time from August 16. He will formally start his position as CFO part-time on June 15, and replace Patrik Renblad who announced his resignation in February.
"We appreciate Patrik's great contribution to SynAct's growth the last couple of years and wish him the best in the future," said Chairman Torbjørn Bjerke.
The information was submitted, through the agency of the contact person below, for publication at 2: 00 p.m CEST on May 15, 2023
For further information, please contact: Torbjørn Bjerke, MD Chairman, SynAct Pharma AB Phone: +46 727 44 41 58 Mail: [email protected] Mail: [email protected]
About SynAct Pharma AB
SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms.
For more information, please visit the company's web page: www.synactpharma.com.